MAGE A4 (230-239)
MAGE A4 (230-239) is a peptide sequence derived from the MAGE-A4 protein. MAGE A4 (230-239) is an immunogenic epitope that can activate T cells and trigger the killing of tumor cells expressing MAGE-A4. MAGE A4 (230-239) is used in the development of next-generation T cell-based immunotherapies[1].
Product Specifications
CAS Number
[252875-61-9]
UNSPSC
12352209
Target
Others
Type
Peptides
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mage-a4-230-239.html
Smiles
O=C(N[C@@H](C(C)C)C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CC(O)=O)C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC2=CNC=N2)C(N[C@@H]([C@H](O)C)C(N[C@@H](C(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CN
Molecular Formula
C48H73N15O17
Molecular Weight
1132.18
References & Citations
[1]Davari K, et al. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy[J]. Journal for Immunotherapy of Cancer, 2021, 9 (3) .
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items